Home/Celldex Therapeutics/James J. Egan, Ph.D.
JJ

James J. Egan, Ph.D.

Director

Celldex Therapeutics

Celldex Therapeutics Pipeline

DrugIndicationPhase
Barzolvolimab (CDX-0159)Chronic Spontaneous Urticaria (CSU)Phase 2b
CDX-1149Solid TumorsPhase 1
CDX-585Solid TumorsPhase 1